Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
8.22 USD +6.06% Intraday chart for Ironwood Pharmaceuticals, Inc. +1.48% -28.15%
03-28 Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) CI
02-29 Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
La biotech helvétique a profité d'un regain de fonds en 2023
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session
Top Premarket Decliners
Ironwood says bowel disease treatment meets main goal in late-stage trial
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024
Ironwood Pharmaceuticals 2024 Revenue Outlook Trails Consensus; 2023 Guidance Maintained
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024
Pharma und Gesundheit: weitere Konsolidierung
Farma en gezondheid: consolidatie gaat door
Farmaceutica e salute: continua il consolidamento
Farmacia y salud: La consolidación continúa
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. News Ironwood Pharmaceuticals, Inc.
  5. Other languages